Tirzepatide is a cutting-edge peptide used for fat loss and glycemic control via dual GLP-1 and GIP receptor agonism. This report summarizes independent lab testing of Peptide Hubs Tirzep 5 mg to verify product integrity and dosing accuracy.
Test Overview
- Test Date: April 22, 2025
- Product: Tirzep 5 mg
- Manufacturer: Peptide Hubs
- Labeled Dosage: 5 mg per 2 mL vial
- Tested Dosage: 5.43 mg
- Purity: 99.473%
Results Summary
The lab results confirmed a total of 5.43 mg of Tirzepatide per vial, exceeding the labeled dosage. Purity was measured at 99.473%, indicating high-quality synthesis and minimal contaminants. These results confirm Peptide Hubs’ consistent manufacturing standards.
Further Reading
For usage guidance, stacking ideas, and user feedback, see our full Peptide Hubs Tirzep review.
Conclusion
Peptide Hubs Tirzep 5 mg has been lab-verified to exceed label claims in both dosage and purity. For users focused on long-term fat loss and glucose control, this peptide offers clinical-grade assurance backed by independent analysis.